X.T.L. Biopharmaceuticals Net Tangible Assets

X.T.L. Biopharmaceuticals posts a net tangible assets of $-250K as of December 2025. That compares with $5.4M in the prior-year period — down 104.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, X.T.L. Biopharmaceuticals's net tangible assets was $5.4M. The latest reading is $-250K — a 104.7% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of X.T.L. Biopharmaceuticals's financial statement story. At $-250K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for XTLB's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; X.T.L. Biopharmaceuticals's other metric pages and overview cover the third.

Judging X.T.L. Biopharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $-250K here, then scan peer and history charts to see if the gap is persistent.